Article Sidebar
Views PDF: 62
EARLY OUTCOMES IN KIDNEY TRANSPLANT PATIENTS WITH A HISTORY OF PRE-EXISTING CANCER
Main Article Content
Abstract
Objective: Immunosuppressive drug treatment after transplantation can exacerbate the underlying conditions of malignant diseases, thereby threatening the patient's life and long-term success of the transplant. Patients and research methods: Clinical description of 4 patients diagnosed with a history of cancer in other organs and successfully treated before undergoing kidney transplantation. Research indicators: age, source of kidney graft, cancer history, treatment outcomes, time from cancer treatment to kidney transplant, pre-transplant cancer assessment, post-transplant outcomes. Results: 3 patients treated for thyroid cancer had intervals between treatment and transplant of 12 months, 14 months, and 5 years. 1 patient diagnosed with T1N0M0 kidney cell cancer received a kidney transplant after 12 months. Pre-transplant PET CT scans were mandatory. Stable kidney transplant results were observed with no graft rejection. Renal function returned to normal, and there was no recurrence of new kidney cancer or infections. Conclusion: Patients with a history of malignancy were successfully treated before transplantation. The time taken for kidney transplantation depended on the type of cance
Article Details
Keywords
kidney transplantation, prior cancer history for solid transplantation
References
2. David P. Al-Adra, Laura Hammel, John Roberts, E. Steve Woodle (2021). Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am. J. Transplant. 2021;21:460–474
3. Sergio A, Rinku Sutradhar, Joseph Kim et al (2018) Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study. Transplantation ;102 : 1156 -1164 . DOI: 10.1097/TP.0000000000002178.
4. Sergio A, Winnnie Lam, Corine Daly et al (2018). Cancer evaluation in the assessment of solid organ transplantation candidates: a systematic review of clinical pratice guidelines. Transplantation reviews, 32,1,pages 29-35. https://doi.org/10.1016/j.trre.2017.10.002
5. Brattstrom C, Granath F, Edgren G, et al. Overall and cause-specificmortality in transplant recipients with a pretransplantation cancer history. Transplantation. 2013;96:297–305
6. G. Mosconi, L. Stalteri, F. Centofanti, I. Capelli, E. Carretta, E. Persici, (2011). Incidence of Cancer in Kidney Transplantation Waiting List Patients A Single Center Experience Transplantation Proceedings, 43, 1003–1005 (2011)
7. Michał Pyrza, Jacek Małyszkob, Paweł Zebrowski, Monika Wieliczkoa, and Jolanta Małyszkoa. (2020). Malignancy Prevalence in Waitlisted Potential Kidney Transplant
Recipients Is Very Low Relative to Patients After Kidney Transplantation. Transplantation Proceedings, 20, 1- 4. https://doi.org/10.1016/ j.transproceed.2020.01.119
8. Fischereder M, Jauch KW. Prevalence of cancer history prior to renal transplantation. Transpl Int 200518, 779 -784.